Tetravalent Bispecific Antibody, Preparation Method Therefor, and Use Thereof
Summary
The European Patent Office published patent application EP3967711A1 for a tetravalent bispecific antibody filed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. The application covers the antibody's preparation method and therapeutic uses. The A1 publication includes a European search report and designates 32 member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.
What changed
EPO published patent application EP3967711A1 filed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. The application claims a tetravalent bispecific antibody, its preparation method, and therapeutic uses including cancer treatment (A61P 35/00, A61P 35/02), respiratory conditions (A61P 11/06), dermatological disorders (A61P 17/00, A61P 17/06), musculoskeletal diseases (A61P 19/02), ocular conditions (A61P 27/02), pain management (A61P 29/00), and autoimmune conditions (A61P 37/02).
For biotechnology companies, pharmaceutical firms, and investors, this publication establishes a priority date and makes the technical details of the bispecific antibody technology publicly available. Competitors researching similar tetravalent antibody formats should review the claims to assess potential freedom-to-operate implications. The designated states indicate the applicants are seeking protection across major European markets. Parties interested in licensing or challenging this technology may now access the full application details through the EPO register.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TETRAVALENT BISPECIFIC ANTIBODY, PREPARATION METHOD THEREFOR, AND USE THEREOF
Publication EP3967711A1 Kind: A1 Apr 08, 2026
Applicants
Sunshine Guojian Pharmaceutical
(Shanghai) Co., Ltd.
Inventors
ZHAO, Jie, HUANG, Haomin, ZHU, Zhenping, ZHU, Yunxia
IPC Classifications
C07K 16/28 20060101AFI20230707BHEP C07K 16/46 20060101ALI20230707BHEP A61K 39/395 20060101ALI20230707BHEP A61P 35/00 20060101ALI20230707BHEP A61P 11/06 20060101ALI20230707BHEP A61P 17/00 20060101ALI20230707BHEP A61P 17/06 20060101ALI20230707BHEP A61P 19/02 20060101ALI20230707BHEP A61P 27/02 20060101ALI20230707BHEP A61P 29/00 20060101ALI20230707BHEP A61P 35/02 20060101ALI20230707BHEP A61P 37/02 20060101ALI20230707BHEP C07K 16/22 20060101ALI20230707BHEP C07K 16/32 20060101ALI20230707BHEP A61K 39/00 20060101ALI20230707BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.